Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel

Khalid A. Mohamedali, Gang Niu, Troy A. Luster, Philip E. Thorpe, Haokao Gao, Xiaoyuan Chen, Michael G. Rosenblum

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

As a part of an ongoing assessment of its mechanism of action, we evaluated the in vivo pharmacokinetics, tissue distribution, toxicity and antitumor efficacy of VEGF121/rGel, a novel fusion protein. Pharmacokinetic studies showed that VEGF121/rGel cleared from the circulation in a biphasic manner with calculated half-lives of 0.3 and 6 h for the alpha and beta phases, respectively. Pharmacokinetic evaluation of 64Cu-DOTA- VEGF121/rGel showed relatively high blood retention 30 min after injection (26.6 ± 1.73% ID/g), dropping to 11.8 ± 2.83% and 0.82 ± 0.11% ID/g at 60 and 240 min post injection, respectively. Tissue uptake studies showed that kidneys, liver and tumor had the highest drug concentrations 48 h after administration. The maximum tolerated dose (MTD), based on a QOD × 5 i.v. administration schedule, was found to be 18 mg/kg with an LD50 of 25 mg/kg. Treatment of BALB/c mice with VEGF 121/rGel at doses up to the MTD caused no alterations in hematologic parameters. However, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) parameters increased in a dose-related manner. The no-observable-adverse-effect-level (NOAEL) was determined to be 20% of the MTD (3.6 mg/kg). VEGF121/rGel treatment of mice bearing orthotopically-placed MDA-MB-231 breast tumors caused increased vascular permeability of tumor tissue by 53% compared to saline-treated controls. Immunohistochemical analysis showed significant tumor hypoxia and necrosis as a consequence of vascular damage. In summary, VEGF121/rGel appears to be an effective therapeutic agent causing focused damage to tumor vasculature with minimal toxic effects to normal organs. This agent appears to be an excellent candidate for further clinical development.

Original languageEnglish (US)
Pages (from-to)1534-1540
Number of pages7
JournalBiochemical Pharmacology
Volume84
Issue number11
DOIs
StatePublished - Dec 1 2012

Fingerprint

Pharmacodynamics
Maximum Tolerated Dose
Tissue Distribution
Blood Vessels
Toxicity
Tumors
Fusion reactions
Pharmacokinetics
Tissue
Neoplasms
Injections
Poisons
Lethal Dose 50
Capillary Permeability
Aspartate Aminotransferases
Alanine Transaminase
Bearings (structural)
Vascular Endothelial Growth Factor A
Appointments and Schedules
Necrosis

Keywords

  • Angiogenesis
  • Necrosis
  • Pharmacokinetics
  • Toxicology
  • Vascular permeability
  • VEGF

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. / Mohamedali, Khalid A.; Niu, Gang; Luster, Troy A.; Thorpe, Philip E.; Gao, Haokao; Chen, Xiaoyuan; Rosenblum, Michael G.

In: Biochemical Pharmacology, Vol. 84, No. 11, 01.12.2012, p. 1534-1540.

Research output: Contribution to journalArticle

Mohamedali, Khalid A. ; Niu, Gang ; Luster, Troy A. ; Thorpe, Philip E. ; Gao, Haokao ; Chen, Xiaoyuan ; Rosenblum, Michael G. / Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. In: Biochemical Pharmacology. 2012 ; Vol. 84, No. 11. pp. 1534-1540.
@article{1a57803f240f4a1096c6efa8bdbc4ca7,
title = "Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel",
abstract = "As a part of an ongoing assessment of its mechanism of action, we evaluated the in vivo pharmacokinetics, tissue distribution, toxicity and antitumor efficacy of VEGF121/rGel, a novel fusion protein. Pharmacokinetic studies showed that VEGF121/rGel cleared from the circulation in a biphasic manner with calculated half-lives of 0.3 and 6 h for the alpha and beta phases, respectively. Pharmacokinetic evaluation of 64Cu-DOTA- VEGF121/rGel showed relatively high blood retention 30 min after injection (26.6 ± 1.73{\%} ID/g), dropping to 11.8 ± 2.83{\%} and 0.82 ± 0.11{\%} ID/g at 60 and 240 min post injection, respectively. Tissue uptake studies showed that kidneys, liver and tumor had the highest drug concentrations 48 h after administration. The maximum tolerated dose (MTD), based on a QOD × 5 i.v. administration schedule, was found to be 18 mg/kg with an LD50 of 25 mg/kg. Treatment of BALB/c mice with VEGF 121/rGel at doses up to the MTD caused no alterations in hematologic parameters. However, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) parameters increased in a dose-related manner. The no-observable-adverse-effect-level (NOAEL) was determined to be 20{\%} of the MTD (3.6 mg/kg). VEGF121/rGel treatment of mice bearing orthotopically-placed MDA-MB-231 breast tumors caused increased vascular permeability of tumor tissue by 53{\%} compared to saline-treated controls. Immunohistochemical analysis showed significant tumor hypoxia and necrosis as a consequence of vascular damage. In summary, VEGF121/rGel appears to be an effective therapeutic agent causing focused damage to tumor vasculature with minimal toxic effects to normal organs. This agent appears to be an excellent candidate for further clinical development.",
keywords = "Angiogenesis, Necrosis, Pharmacokinetics, Toxicology, Vascular permeability, VEGF",
author = "Mohamedali, {Khalid A.} and Gang Niu and Luster, {Troy A.} and Thorpe, {Philip E.} and Haokao Gao and Xiaoyuan Chen and Rosenblum, {Michael G.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1016/j.bcp.2012.09.017",
language = "English (US)",
volume = "84",
pages = "1534--1540",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel

AU - Mohamedali, Khalid A.

AU - Niu, Gang

AU - Luster, Troy A.

AU - Thorpe, Philip E.

AU - Gao, Haokao

AU - Chen, Xiaoyuan

AU - Rosenblum, Michael G.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - As a part of an ongoing assessment of its mechanism of action, we evaluated the in vivo pharmacokinetics, tissue distribution, toxicity and antitumor efficacy of VEGF121/rGel, a novel fusion protein. Pharmacokinetic studies showed that VEGF121/rGel cleared from the circulation in a biphasic manner with calculated half-lives of 0.3 and 6 h for the alpha and beta phases, respectively. Pharmacokinetic evaluation of 64Cu-DOTA- VEGF121/rGel showed relatively high blood retention 30 min after injection (26.6 ± 1.73% ID/g), dropping to 11.8 ± 2.83% and 0.82 ± 0.11% ID/g at 60 and 240 min post injection, respectively. Tissue uptake studies showed that kidneys, liver and tumor had the highest drug concentrations 48 h after administration. The maximum tolerated dose (MTD), based on a QOD × 5 i.v. administration schedule, was found to be 18 mg/kg with an LD50 of 25 mg/kg. Treatment of BALB/c mice with VEGF 121/rGel at doses up to the MTD caused no alterations in hematologic parameters. However, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) parameters increased in a dose-related manner. The no-observable-adverse-effect-level (NOAEL) was determined to be 20% of the MTD (3.6 mg/kg). VEGF121/rGel treatment of mice bearing orthotopically-placed MDA-MB-231 breast tumors caused increased vascular permeability of tumor tissue by 53% compared to saline-treated controls. Immunohistochemical analysis showed significant tumor hypoxia and necrosis as a consequence of vascular damage. In summary, VEGF121/rGel appears to be an effective therapeutic agent causing focused damage to tumor vasculature with minimal toxic effects to normal organs. This agent appears to be an excellent candidate for further clinical development.

AB - As a part of an ongoing assessment of its mechanism of action, we evaluated the in vivo pharmacokinetics, tissue distribution, toxicity and antitumor efficacy of VEGF121/rGel, a novel fusion protein. Pharmacokinetic studies showed that VEGF121/rGel cleared from the circulation in a biphasic manner with calculated half-lives of 0.3 and 6 h for the alpha and beta phases, respectively. Pharmacokinetic evaluation of 64Cu-DOTA- VEGF121/rGel showed relatively high blood retention 30 min after injection (26.6 ± 1.73% ID/g), dropping to 11.8 ± 2.83% and 0.82 ± 0.11% ID/g at 60 and 240 min post injection, respectively. Tissue uptake studies showed that kidneys, liver and tumor had the highest drug concentrations 48 h after administration. The maximum tolerated dose (MTD), based on a QOD × 5 i.v. administration schedule, was found to be 18 mg/kg with an LD50 of 25 mg/kg. Treatment of BALB/c mice with VEGF 121/rGel at doses up to the MTD caused no alterations in hematologic parameters. However, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) parameters increased in a dose-related manner. The no-observable-adverse-effect-level (NOAEL) was determined to be 20% of the MTD (3.6 mg/kg). VEGF121/rGel treatment of mice bearing orthotopically-placed MDA-MB-231 breast tumors caused increased vascular permeability of tumor tissue by 53% compared to saline-treated controls. Immunohistochemical analysis showed significant tumor hypoxia and necrosis as a consequence of vascular damage. In summary, VEGF121/rGel appears to be an effective therapeutic agent causing focused damage to tumor vasculature with minimal toxic effects to normal organs. This agent appears to be an excellent candidate for further clinical development.

KW - Angiogenesis

KW - Necrosis

KW - Pharmacokinetics

KW - Toxicology

KW - Vascular permeability

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84868476397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868476397&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2012.09.017

DO - 10.1016/j.bcp.2012.09.017

M3 - Article

C2 - 23022224

AN - SCOPUS:84868476397

VL - 84

SP - 1534

EP - 1540

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 11

ER -